SUMO2, Recombinant, Human (Small Ubiquitin-Related Modifier 2, Sentrin2, SMT3B)
Catalog No : USB-209217
473.58€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | SUMO2, Recombinant, Human (Small Ubiquitin-Related Modifier 2, Sentrin2, SMT3B) | ||
|---|---|---|---|
| Catalog No | USB-209217 | ||
| Supplier’s Catalog No | 209217 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, E. coli | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 11 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (RP-HPLC, SDS-PAGE) | ||
| Form | Supplied as a lyophilized powder in PBS, pH 7.4. No preservative added. Reconstitute with 100ul sterile ddH2O. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (RP-HPLC, SDS-PAGE) | ||
| Description | Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site. Human SUMO2, also known as Sentrin2 and SMT3B is synthesized as a 95aa, 11kD propeptide that contains a two aa C-terminal prosegment, and an 18aa N-terminal protein interacting region (aa33-50). Source: Recombinant protein corresponding to human SUMO2, a single, non-glycosylated polypeptide chain containing 95aa, expressed in E. coli. Molecular Weight: ~11kD Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved